Concepedia

Zhihong Zeng

ZZ

8

Publications

858

Citations

8

H-Index

2006

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Zhihong Zeng is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, pharmacotherapy, and medicine.

Top concepts

Publications per year

2006–2024

8

Publications

8

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML

Zhihong Zeng, Dos D. Sarbassov, Ismael Samudio et al. · Blood · 2006 · 342 citations · Full text

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen Yee, Zhihong Zeng, Marina Konopleva et al. · Clinical Cancer Research · 2006 · 287 citations

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, Yanis Boumber, Hagop M. Kantarjian et al. · Clinical Cancer Research · 2015 · 67 citations · Full text

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.

Curtis A. Lachowiez, Gautam Borthakur, Sanam Loghavi et al. · Journal of Clinical Oncology · 2020 · 56 citations

, , +18

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

Brittany Knick Ragon, Hagop M. Kantarjian, Elias Jabbour et al. · American Journal of Hematology · 2016 · 52 citations · Full text

, , +16

Rows per page

1–5 of 8